Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novavax

7.70
+0.01670.22%
Volume:2.57M
Turnover:19.95M
Market Cap:1.24B
PE:-6.25
High:8.12
Open:7.75
Low:7.48
Close:7.68
Loading ...

Company Profile

Company Name:
Novavax
Exchange:
NASDAQ
Establishment Date:
1987
Employees:
952
Office Location:
700 Quince Orchard Road,Gaithersburg,Maryland,United States
Zip Code:
20878
Fax:
- -
Introduction:
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Directors

Name
Position
Stanley C. Erck
Director,President and Chief Executive Officer
James F. Young
Director and chairman
David M. Mott
Director
Gary C. Evans
Director
Gregg H. Alton
Director
Margaret G. McGlynn
Director
Michael A. McManus, Jr.
Director
Rachel K. King
Director
Rajiv I. Modi
Director
Richard H. Douglas
Director

Shareholders

Name
Position
Stanley C. Erck
Director,President and Chief Executive Officer
John Trizzino
Executive Vice President,Chief Commercial Officer,Chief Business Officer and Interim Chief Financial Officer
Gregory Glenn
President, Research and Development
John A. Herrmann III
Executive Vice President,Chief Legal Officer and Corporate Secretary